CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of “Hold” from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has received an average rating of “Hold” from the sixteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $76.29.

A number of research firms recently issued reports on CRSP. Royal Bank of Canada lifted their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research note on Thursday, February 22nd. Wells Fargo & Company lifted their price target on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, February 22nd. Wolfe Research began coverage on shares of CRISPR Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Mizuho lifted their price target on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Finally, Barclays lifted their target price on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 22nd.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 50,000 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the sale, the chief executive officer now owns 187,377 shares in the company, valued at $11,338,182.27. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 133,992 shares of company stock worth $9,157,835. Company insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

A number of large investors have recently made changes to their positions in CRSP. Price T Rowe Associates Inc. MD increased its stake in shares of CRISPR Therapeutics by 158.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,014,551 shares of the company’s stock worth $183,194,000 after buying an additional 1,848,437 shares during the period. ARK Investment Management LLC increased its stake in shares of CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after buying an additional 1,372,986 shares during the period. State Street Corp increased its stake in shares of CRISPR Therapeutics by 228.8% during the second quarter. State Street Corp now owns 1,569,860 shares of the company’s stock worth $95,400,000 after buying an additional 1,092,384 shares during the period. BlackRock Inc. increased its stake in shares of CRISPR Therapeutics by 79.2% during the first quarter. BlackRock Inc. now owns 2,278,774 shares of the company’s stock worth $143,038,000 after buying an additional 1,007,246 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of CRISPR Therapeutics by 261.4% during the first quarter. Vanguard Group Inc. now owns 1,217,289 shares of the company’s stock worth $76,410,000 after buying an additional 880,463 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $55.05 on Monday. The firm has a market cap of $4.67 billion, a price-to-earnings ratio of -28.09 and a beta of 1.76. The company has a 50 day moving average price of $72.96 and a 200-day moving average price of $63.52. CRISPR Therapeutics has a 1-year low of $37.55 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to analysts’ expectations of $148.72 million. During the same period last year, the firm earned ($1.41) earnings per share. CRISPR Therapeutics’s revenue for the quarter was up 3253.3% compared to the same quarter last year. On average, sell-side analysts anticipate that CRISPR Therapeutics will post -6.24 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.